You’ll never be 100% sure if a patient has bipolar, ADHD, or both, but we’ll get you as close as we can.

How to assess med response when the patient reports is a poor guide: long-term mood stabilizers, sleep meds, and rapid cycling.

A new med combo for alcohol use disorder, antipsychotic dose reduction in schizophrenia, and two new tips for using stimulants in ADHD.

New studies change how we think about lithium and weight gain, and updates on lumateperone, lavender, and esketamine in depression. 

We count down the top 10 research updates of the past year with a focus on treatment resistant depression and benzo withdrawal.

KarXT (Cobenfy) is the first antipsychotic that doesn’t block dopamine. We trace the origins of this new drug to a South Asian herb used for over 5,000 years, up to the three EMERGENT trials that led to its FDA approval.

A new medication is knocking on the door for FDA approval in PTSD, and it isn’t MDMA. We cover that, and 8 other off label medications.

Should we follow the FDA and give SSRIs, or venture off-label with the fabled prazosin?

0.25 CME Credits. In this episode, we explore nine groundbreaking stories in mental health and psychiatric medicine, covering everything from healthcare fraud to the latest advancements in drug trials. First, we dive into the recent charges brought by the US Department of Justice against executives at Done, a California-based telehealth company, for alleged healthcare fraud. Done is accused of prescribing over 40 million Adderall pills to patients without proper evaluation, raising concerns about the balance between increasing mental healthcare access and responsible prescribing practices.

Learn what therapies work for PTSD, what goes on in session, and how to prevent PTSD when your patient calls after a trauma.